Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer

Matteo Ligorio, Srinjoy Sil, Jose Malagon-Lopez, +45

Cell

Pancreatic CancerBiological MicroenvironmentsMedicineRadiation OncologyTumor Microenvironment +1

Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features

Rémi Buisson, Adam Langenbucher, Danae Bowen, +4

Science

EngineeringGeneticsTumor HeterogeneityCancer GenomesMolecular Diagnostics +16

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Michael S. Lawrence, Benjamin J. Burke, +21

Cancer Discovery

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Leila Dardaei, Hui Qin Wang, Manrose Singh, +31

Nature Medicine

Alk InhibitorsMedicinePharmacologyBronchial NeoplasmImmune Checkpoint Inhibitor +6

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Ibiayi Dagogo‐Jack, Satoshi Yoda, Jochen K. Lennerz, +19

Clinical Cancer Research

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer

Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, +23

Clinical Cancer Research

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, +37

Nature

Tumor BiologyMedicineTumor SuppressorCancer BiologyCell Biology +2

Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots

Pégah Jalili, Danae Bowen, Adam Langenbucher, +5

Nature Communications

An extended APOBEC3A mutation signature in cancer

Adam Langenbucher, Danae Bowen, Ramin Sakhtemani, +6

Nature Communications

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition

Adam Langenbucher, Pranav Gupta, Satoshi Yoda, +17

npj Precision Oncology